| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2693 |
| Trial ID | NCT04892277 |
| Disease | Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | B-Cell Non-Hodgkin's Lymphoma | Refractory B-Cell Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | IC19/1563 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies |
| Year | 2021 |
| Country | United States |
| Company sponsor | Mayo Clinic |
| Other ID(s) | MC198A|NCI-2021-03969 |
| Cohort 1 | |||||||||||
|
|||||||||||